PrecisionLife TRANSCEND Project Wins EIC Award to Detect and Treat Endometriosis

Oxford-based PrecisionLife has been awarded a €2.5 million non-dilutive grant from the European Innovation Council (EIC) for its TRANSCEND project, which aims to improve the diagnosis and treatment of endometriosis. Using unique insights into the biological mechanisms of this complex disease, the company will develop and validate a rapid, non-invasive precision medicine test to assess a patient’s risk and identify targeted treatment options.

Endometriosis affects 190 million women worldwide, often causing severe pain, infertility, and an increased risk of ovarian cancer. Currently, there is no screening method, and diagnosis can take up to a decade, requiring invasive surgery. PrecisionLife’s test, using a simple buccal swab, will enable faster and more accurate triage of patients, helping doctors determine their risk and refer them to the appropriate specialist. It will also support the development of new treatment options, including repurposed drugs identified by PrecisionLife.

The clinical validation of this test will not only improve patient outcomes but also create a path for reimbursement and streamline clinical trials for new therapies. “We are grateful to the EIC for recognizing the urgent need for better diagnostics and treatments for endometriosis,” said Steve Gardner, CEO of PrecisionLife. He continued:

Project TRANSCEND will transform the lives of millions of women, reducing the burden of this debilitating disease while delivering cost savings for healthcare systems.

PrecisionLife was one of 71 companies selected for this round of EIC funding from over 1,200 applicants, marking one of the most competitive funding rounds since the launch of the Accelerator under Horizon Europe in 2021.